Navigation Links
Tau transmission model opens doors for new Alzheimer's, Parkinson's therapies
Date:3/15/2013

SAN DIEGO Injecting synthetic tau fibrils into animal models induces Alzheimer's-like tau tangles and imitates the spread of tau pathology, according to research from the Perelman School of Medicine at the University of Pennsylvania being presented at the American Academy of Neurology's 65th Annual Meeting in San Diego March 16-23, 2013.

This Alzheimer's research, along with additional Parkinson's research from Penn and beyond, further demonstrates the cell-to-cell transmission of neurodegenerative proteins. John Q. Trojanowski, MD, PhD, co-director of the Center for Neurodegenerative Disease Research (CNDR) and professor of Pathology and Laboratory Medicine at the Perelman School of Medicine, University of Pennsylvania, will present the research in the Hot Topics plenary session on Tuesday, March 19 starting at 5:15pm.

"The transmission model better explains the spread of disease within neurodegenerative disease, and has uncovered new therapeutic opportunities which we are exploring vigorously," said Dr. Trojanowski. "However, it is important to emphasize that the spread of Alzheimer's and Parkinson's pathology does not mean these diseases are infectious, like Mad Cow disease, based on data from another recent study from our group."


'/>"/>

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-200-2312
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1

Related medicine news :

1. Bacterial Vaginosis Increases Female-to-Male HIV Transmission Risk
2. Glutamate neurotransmission system may be involved with depression risk
3. Tracking the spread of dengue fever: Domestic networks drive rapid transmission of human infection
4. Brain-to-brain interface allows transmission of tactile and motor information between rats
5. Researchers develop a new cell and animal model of inflammatory breast cancer
6. Model for breast cancer rehab featured in supplement to ACS journal, Cancer
7. Research shows efficacy of treatment model developed at Women & Infants
8. HHS enlists Archimedes Inc. to expand governments use of health care modeling
9. Modeling the demise of migrating brain tumor cells
10. Super Models Line Up to Walk The Catwalk and Celebrate Vogue's Fashion Night Out in LA
11. Nerve growth factors elevated in pancreatic cancer model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: